| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Leukotriene E4, Random, Urine
MessageSendout, Mayo test code: RLTE4
Test Code
LAB5211854
Alias/See Also
Cysteinyl Leukotriene
LTE4
Mast Cell Activation Syndrome
Mastocytosis
Systemic Mast Cell Activation
Secondary MCAS
Aspirin-exacerbated respiratory disease (AERD)
Asthma
IgE-dependent and independent asthma
Idiopathic MCAS
RLTE4
LTE4
Mast Cell Activation Syndrome
Mastocytosis
Systemic Mast Cell Activation
Secondary MCAS
Aspirin-exacerbated respiratory disease (AERD)
Asthma
IgE-dependent and independent asthma
Idiopathic MCAS
RLTE4
CPT Codes
82542, 82570
Preferred Specimen
5 mL random urine in a sterile container
Minimum Volume
2 mL
Instructions
1. Within a few hours of symptom onset, collect a random urine specimen.
2. No preservative
3. Aliquot urine into a plastic vial and send frozen.
2. No preservative
3. Aliquot urine into a plastic vial and send frozen.
Transport Container
Plastic vial
Transport Temperature
Frozen (preferred)
Specimen Stability
Frozen (preferred): 30 days
Refrigerated: 7 days
Ambient: 24 hour
Refrigerated: 7 days
Ambient: 24 hour
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.
Methodology
LTE4R: Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
CRTFR: Enzymatic Colorimetric Assay
FDA Status
Approved
Setup Schedule
Monday, Thursday
Report Available
2 to 9 days
Limitations
Patients taking the 5-lipoxygenase inhibitor zileuton (Zyflo) may have decreased concentrations of leukotriene E4 (LTE4) if the dosage has not been discontinued for 48 hours.
Mast cell (MC) activation disorder is a heterogenous disease, and the absence of elevated LTE4 does not exclude the diagnosis of MC disease.
Increased excretion of LTE4 is nonspecific and should not be used alone to make a clinical diagnosis of a MC activation disease.
This assay measures both LTE4 and the 11-trans-LTE4 as markers of MC release.
Mast cell (MC) activation disorder is a heterogenous disease, and the absence of elevated LTE4 does not exclude the diagnosis of MC disease.
Increased excretion of LTE4 is nonspecific and should not be used alone to make a clinical diagnosis of a MC activation disease.
This assay measures both LTE4 and the 11-trans-LTE4 as markers of MC release.
Reference Range
Included with report
Clinical Significance
Aiding in the evaluation of patients at-risk for mast cell activation syndrome (eg, systemic mastocytosis, IgE-mediated allergies, or aspirin-exacerbated respiratory disease) using random urine collections
Performing Laboratory
Mayo Clinic Laboratories, Rochester, Minnesota
Additional Information
Leukotriene E4, Random, Urine
